What's hot

View all perspectives
What's Hot

JAK Safety -- The Lowdown on Infection: Drs. Kevin Winthrop and Jonathan Kay

Watch video →

RheumNow Rheumatology Roundup: Drs. Kavanaugh and Cush

Rheumatology Roundup! Drs. Cush and Kavanaugh convene for their annual impromptu review of some of the best and more interesting abstracts presented at ACR 2021.    

Watch video →

TNF Inhibitor Panel Discussion: ACR21 Annual Meeting

RheumNow TNFi faculty convened to discuss several TNFi-related abstracts presented at ACR 21. Panelists: Drs. Aurelie Najm, Janet Pope, David Liew, Eric Dein and Swetha Alexander. 

Watch video →

Spondyloarthritis Panel Discussion: ACR21 Meeting

Panelists: Drs. Antoni Chan, Robert Chao, Rachel Tate, Sheila Reyes and Akhil Sood. Abstracts discussed include #0562, #1919, #0907, #0364 and #0919

Watch video →

Might Tofacitinib Reduce Malignancy Risk with Patients with RA? Dr. Jonathan Kay

Dr. Kay discusses abstract 1940 and abstract 980 presented at the ACR21 annual meeting.

Watch video →

Diagnosing (Bad) VEXAS: The Experts Speak Drs. Beck and Ferrada

Dr. Cush discusses Dr. Marcela Ferrada and Dr. David Beck to discuss VEXAS syndrome and abstract 1426, which was presented at the ACR21 annual meeting.

Watch video →

Pediatric Psoriatic Arthritis: Dr. Eric Ruderman

Dr. Ruderman discusses abstracts #1424 presented at the ACR21 annual meeting.

Watch video →

Urine Proteome Advances: What Do They Mean? Dr. Michelle Petri

Dr. Petri reviews abstracts #1422 and #1936, presented at the ACR21 annual meeting.

Watch video →

ACR21 Day 3 Recap: Polypharmacy, New Lupus Drugs, VEXAS, Safety Data

Blurb: Drs. Jack Cush and the RheumNow Faculty Drs. Akhil Sood, Antoni Chan, Olga Petryna and Eric Dein, discuss highlights from Day 3 (Monday) at the ACR21 annual meeting. Abstracts include #1367, #1044, #1444, #1083 and more.

Watch video →

Cardiovascular Disease for TNFi vs JAKi: Dr Jon Giles

Dr. Giles discusses abstracts #0831and #0958 presented at the ACR21 annual meeting.

Watch video →

Predictors of TNF Response with Drs. Pope, Dein and Liew

Drs. Janet Pope, David Liew and Eric Dein discuss TNF data presented at the ACR21 annual meeting, including abstracts #1251, #1442, #1448.

Watch video →

Caring for the Older Patient with Rheumatic Disease: Drs. Makris, Yung and Dao

Drs. Kathryn Dao, Una Makris and Raymond Yung discuss the field of geriatric rheumatology and caring for the older patient with rheumatic disease.

Watch video →

Autoinflammatory: PAH in AOSD, VEXAS, JAKi in Still's, Role of labs in infections vs. flares

  Drs. Jack Cush, Yuz Yusof, Bella Mehta, Olga Petryna and Rachel Tate review autoinflammatory data presented at the ACR21 annual meeting, including abstracts #1100, #1062, #1426, #0252, #0195, and #1083.

Watch video →

FDA Session Review: Dr. Arthur Kavanaugh

Dr. Kavanaugh discussed the FDA session presented at the ACR21 annual meeting, including safety data and new approvals and indications in several rheumatic diseases, including lupus, ANCA-associated vasculitis, lupus nephritis and more.

Watch video →

The Respiratory Tract and RA with Drs. Sparks, McDermott and Kronzer

Drs. Jeffrey Sparks, Greg McDermott and Vanessa Kronzer discuss work in the area of respiratory disease in RA, mucosal paradigm, RA-ILD, bronchiectasis, as well as their experience as virtual attendees at the ACR21 annual meeting.

Watch video →

Pulmonary Hypertension in Adult Onset Still's Disease: Dr. Jack Cush

Dr. Cush reviews poster #1100 presented at the ACR21 annual meeting.

Watch video →

Data on Existing SLE Medications, Patient Centered Outcomes, and Exercise: Dr. Michelle Petri

Dr. Petri discusses data on existing SLE medications, patient-centered outcomes and the importance of exercise, presented Monday at the ACR21 annual meeting.

Watch video →

ACR21 Day 2 Recap: CV Risk, Tapering in SpA, Microbiome in PsA, Vit D

Drs. Jack Cush and the RheumNow Faculty Drs. David Liew, Swetha Ann Alexander, Meral El Ramahi, Mrinalini Dey and Robert Chao, discuss highlights from Day 2 (Sunday) at the ACR21 Virtual meeting.

Watch video →
      RT @DrPetryna: Abst1314 #acr21 @RheumNow factors associated w/ Acute anterior uveitis in AxSpA:
      -history of AAU
      -male g

      Olga Petryna DrPetryna

      4 years ago
      Abst1314 #acr21 @RheumNow factors associated w/ Acute anterior uveitis in AxSpA: -history of AAU -male gender - presence of extraspinal involvement -concomitant cs-DMARD usage -BASDAI scores ASDAS-CRP, and PGA of disease activity. https://t.co/4YA8dSJzy3
      RT @synovialjoints: Raised BMI is related to poorer outcomes to biologics in PsA. The mean change in outcome measures (c

      Dr. Antoni Chan synovialjoints

      4 years ago
      Raised BMI is related to poorer outcomes to biologics in PsA. The mean change in outcome measures (cDAPSA, RAPID3, PsAID) was lowest among obese patients . This was observed primarily among TNFi initiators vs to OSM or IL17i @RheumNow #ACR21 Abstr#1327 https://t.co/pm7PPp9UH4 https://t.co/j5GWpCBD2d
      RT @uptoTate: Real-world PsA study: MDA assoc'd w/ higher probability of achieving clinically meaningful improvements in

      Dr. Rachel Tate uptoTate

      4 years ago
      Real-world PsA study: MDA assoc'd w/ higher probability of achieving clinically meaningful improvements in dz activity & PROMs. MDA pts more likely w/ b/tsDMARDs, but found in less than 25% of pts in COREVITAS cohort. Abs 1344 #ACR21 #RheumNow @RheumNow https://t.co/RrAfXvn4kf https://t.co/TjPCwzYfZK
      RT @drdavidliew: How does @US_FDA see Tyk2 inh: part of or separate to JAKi class?

      “I don’t think I’m in a positi

      David Liew drdavidliew

      4 years ago
      How does @US_FDA see Tyk2 inh: part of or separate to JAKi class? “I don’t think I’m in a position to make a call on this at this meeting, but certainly Tyk2 is a JAK” Tantalising end to a great session at #ACR21. Feels like the audience could have questions for days. @RheumNow
      RT @ericdeinmd: #ACR21 plenary#1424. JUNIPERA study for Secukinumab for ERA, JPsA
      ⭐️Time to disease flare longer in

      Eric Dein ericdeinmd

      4 years ago
      #ACR21 plenary#1424. JUNIPERA study for Secukinumab for ERA, JPsA ⭐️Time to disease flare longer in SEC vs PBO ⭐️Sustained improvement up to wk 104 ▶️Rapid decrease of JADAS-27 in initial open-label portion of study https://t.co/m5bl9Ho163 @Rheumnow https://t.co/wnEdxeYfjh
      RT @swethaann23: Network meta-analysis assessed comparative risk of respiratory tract infection (RTI) with different b/t

      swethaann23 swethaann23

      4 years ago
      Network meta-analysis assessed comparative risk of respiratory tract infection (RTI) with different b/ts DMARD in PsA ⭐️Abatacept 🔽likelihood RTIs compared ADM/ apremilast/ CTZ/ GOL/TOF ⭐️Apremilast 🔼likelihood RTIs compared INX /secukinumab Abst # 1359 #ACR21 @RheumNow
      RT @DrPetryna: Abst1305 #acr21 @RheumNow undiagnosed depression in AxSpA: 9.9% pts w/abnormal HADs-D scores,23.9% modera

      Olga Petryna DrPetryna

      4 years ago
      Abst1305 #acr21 @RheumNow undiagnosed depression in AxSpA: 9.9% pts w/abnormal HADs-D scores,23.9% moderate to severe PHQ-9 scores. F had higher mean HADs-D scores than M, w/abnormal scores in 19% of F & 6% M. significantly worse BASDAI&AQoL scores in axSpA pts w/abnormal HADs-D https://t.co/sPkGPcITCs
      RT @bella_mehta: Knee OA novel measure of structure and function - Quantitative radiographic OA scores (QROS) software t

      Bella Mehta bella_mehta

      4 years ago
      Knee OA novel measure of structure and function - Quantitative radiographic OA scores (QROS) software that measures medial minimum joint space width (mJSW) and other measures in the tibiofemoral compartment predicts time to TKA. Model well calibrated @rheumnow #ACR21 #abst1051 https://t.co/9LKlb7bZO0
      RT @RHEUMarampa: Characteristics of #uveitis w/axSpA seen in patients of this study:
      👁‍🗨14.6%➡uveitis
      👁‍ð

      sheila RHEUMarampa

      4 years ago
      Characteristics of #uveitis w/axSpA seen in patients of this study: 👁‍🗨14.6%➡uveitis 👁‍🗨All acute, anterior & 93% unilateral 👁‍🗨Delay in dx & ⬆ HLAB27+ No diff. in TNFi use Consistent fact: Uveitis is the ⬆ common extra-articular manifestation in axSPA @RheumNow #ACR21 abs1324 https://t.co/6qC8RxxBrM
      RT @uptoTate: Study comparing TNFi vs SEC in PsA pts w/ active US confirmed enthesitis finds superiority of TNFi (ADA, C

      Dr. Rachel Tate uptoTate

      4 years ago
      Study comparing TNFi vs SEC in PsA pts w/ active US confirmed enthesitis finds superiority of TNFi (ADA, CTZ, ETN) in regards to active entheseal disease. Abs 1356 #ACR21 #RheumNow @RheumNow https://t.co/BvZZsTP3Ta https://t.co/G5cWrQgqDC
      RT @ericdeinmd: #ACR21 Abs#1425. AURORA2 - voclosporin for LN extension
      ⭐️216/357 pts continued into 2-yr study
      ⭐ï

      Eric Dein ericdeinmd

      4 years ago
      #ACR21 Abs#1425. AURORA2 - voclosporin for LN extension ⭐️216/357 pts continued into 2-yr study ⭐️Mean UPCR at month 30: 0.58 in VOC vs 1.3 control. eGFR ⬇️ in VOC, remains stable ⭐️No new AEs @Rheumnow https://t.co/m5bl9Ho163 https://t.co/VVGOCd9vmC
      RT @bella_mehta: What better than a tweet on a #ACR21 study of tweets! 😂
      Using Twitter Firehose data stream - yes we

      Bella Mehta bella_mehta

      4 years ago
      What better than a tweet on a #ACR21 study of tweets! 😂 Using Twitter Firehose data stream - yes we should do a study just during the ACR week...! Fake tweets exists but low in the rheumatology community! @rheumnow #abst1068 Paper - https://t.co/ekguL5qXen https://t.co/rfy7vZlXOn
      RT @DrPetryna: Abst1356 #acr21 @RheumNow TNFi vs SEC in active US confirmed enthesitis: mean ActiveMASEI score ⬇️ 4.

      Olga Petryna DrPetryna

      4 years ago
      Abst1356 #acr21 @RheumNow TNFi vs SEC in active US confirmed enthesitis: mean ActiveMASEI score ⬇️ 4.37 w/TNFi vs 2.22 secukinumab (p = 0.030). Secucinumab leads in regards to the PASI & DLQI score with Sec vs TNFi ( 3.44 vs 1.03 p = 0.001 & 5.57 vs 1.35 p = 0.005 respectively https://t.co/fGTxzvGY99
      RAPID3 in Psoriatic Arthritis: Dr. Meral El Ramahi
      4 years ago
      First JAKi Failure: What next? Dr. Aurelie Najm
      4 years ago

      Podcasts

      • Giant Cell Arteritis and Polymyalgia Rheumatic Wrapup: Drs. Calabrese, Liew, Conway and Mackie 00:20:18
      • Reproductive Health in Rheumatic Diseases: Drs. Bermas, Buyon and Dao 00:20:26
      • The Expert Gout Panel with Drs. Neogi, Saag, Pillinger, Cush and O'Dell 00:35:26

      Catch up on Conference Podcasts

      ×